AstraZeneca Halts Crestor Trial After Early Success

Drug Industry Daily
AstraZeneca is stopping a clinical trial of its cardiovascular drug Crestor early “because there is unequivocal evidence of a reduction in cardiovascular morbidity and mortality” among patients who took the drug compared with those on a placebo, the company said.

To View This Article:


Subscribe To Drug Industry Daily